Nanozola subcutaneous injection 30mg autoinjector, manufactured by Taisho Pharmaceutical, contains Ozoralizumab (recombinant). Ozoralizumab is a humanized trivalent Nanobody compound and a next-generation TNF inhibitor, approved for the treatment of rheumatoid arthritis (RA). It effectively neutralizes TNF-alpha action. It is supplied as a 30mg/0.375mL/1 kit injectable drug (YJ code: 3999467G2020).
Nanozola subcutaneous injection 30mg autoinjector
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →